Business
Alector to Present at Upcoming Virtual Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering
About this update from Alector, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming virtual investor conferences: Citi’s 16th Annual Biopharma Virtual Conference Wednesday, September 8, 2021 at 11:35 a.m. ET, What’s Next for Neurodegenerative Diseases PanelThursday, September 9, 2021 at 1:25 p.m. ET, Fireside Chat The 2021 Wells Fargo Virtual Healthcare Conference Friday, September 10, 2021 at 2:00 p.m. ET, Corporate Presentation The Morgan Stanley 19th Annual Global Healthcare Conference Monday, September 13, 2021 at 11:45 a.m. ET, Fireside Chat Live webcasts of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 30 days following the presentation dates. About AlectorAlector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com. Alector ContactsMichelle CorralVP, Communications and Investor [email protected] 1AB (media)Dan [email protected] Argot Partners (investors)Laura Perry/Eric KasperArgot [email protected] \nSource: Alector, Inc.","length":4543,"tagName":"div"}]